Walter Taal - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Papers authored by Walter Taal

This paper is made freely available by the publisher.

2016 Lale Erdem-Eraslan, Martin J. van den Bent, Youri Hoogstrate

ORCID

, M. J. (Martin) van den Bent, Hina Naz-Khan, Andrew Stubbs, Peter van der Spek, R. Bottcher, René Böttcher, P. J. (Peter) van der Spek, Ya Gao, Maurice de Wit, Walter Taal

ORCID

, Hendrika M. (Hendrika M) Oosterkamp, M. (Maurice) De Wit and 11 other authors

Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial

Download from aacrjournals.org

This paper was not found in any repository, but could be made available legally by the author.

2015 Linda Dirven, Martin J. van den Bent, Andrew Bottomley, Nelly van der Meer, Bronno van der Holt

ORCID

, Maaike J. Vos, Annemiek M. E. Walenkamp, Laurens V. Beerepoot, Monique C. J. Hanse, Jaap C. Reijneveld, Aja Otten, Filip Y. F. L. de Vos

ORCID

, Marion Smits, Jacoline E. C. Bromberg, Walter Taal

ORCID

and 2 other authors

The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial

Upload

This paper is made freely available by the publisher.

N. Beije, J. Kraan

ORCID

, W. Taal

ORCID

, B. van der Holt

ORCID

, Hm M. Oosterkamp, Am M. Walenkamp, L. Beerepoot, M. Hanse, Me E. van Linde, A. Otten, Rm M. Vernhout, F. Y. F. de Vos, Jw W. Gratama, S. Sleijfer, Mj J. van den Bent

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

Download from www.nature.com

This paper is made freely available by the publisher.

Walter Taal

ORCID

, Jacoline Ec C. Bromberg, Martin J. van den Bent

Chemotherapy in glioma

Download from doi.org

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

van der Linden Ym, Yvette M. van der Linden, Rolf Ca, Christa A. M. Rolf, Alexander de Graeff, P. D. S. Sander Dijkstra, Dijkstra Pd, Kuijlen Jm, Jos M. A. Kuijlen, Walter Taal

ORCID

[Alarm symptoms of spinal metastases in patients with cancer].

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Marion Smits, Linda Bralten, Bas Jasperse, Walter Taal

ORCID

, Renske Gahrmann, Annemiek Walenkamp, Rianne Oosterkamp, Rene Vernhout, Bronno van der Holt, Martin van den Bent

Atct-31central Radiology Review of the Belob Trial: Treatment With Bevacizumab in Recurrent Glioblastoma Is Associated With More Frequent Non-Enhancing Progression

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Walter Taal

ORCID

, Alexandra C. M. van der Togt-Van Leeuwen

[New Dutch guideline on spinal metastasis: extended to include spinal localisations of haematological malignancies]

Upload

This paper is made freely available by the publisher.

2014 Walter Taal

ORCID

, Carin C. D. van der Rijt

ORCID

, Winand N. M. Dinjens, Peter A. E. Sillevis Smitt, Agnes A. A. C. M. Wertenbroek, Jacoline E. C. Bromberg, Irene van Heuvel, Johan M. Kros, Martin J. van den Bent

Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics

Download from academic.oup.com

This paper was not found in any repository, but could be made available legally by the author.

Martin J. van den Bent, Walter Taal

ORCID

, Co Investigators Belob

Bevacizumab alone or in combination with chemotherapy in glioblastomas?–Authors' reply

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Walter Taal

ORCID

, Hendrika M. Oosterkamp, Annemiek M. E. Walenkamp, Hendrikus J. Dubbink, Laurens V. Beerepoot, Monique C. J. Hanse, Jan Buter, Aafke H. Honkoop, Dolf Boerman, Filip Y. F. de Vos

ORCID

, Winand N. M. Dinjens, Roelien H. Enting, Martin J. B. Taphoorn, Franchette W. P. J. van den Berkmortel, Rob L. H. Jansen and 6 other authors

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Upload

This paper is available in a repository.

Martin J. van den Bent, Walter Taal

ORCID

Are we done with dose-intense temozolomide in recurrent glioblastoma?

Download from www.ncbi.nlm.nih.gov

This paper is made freely available by the publisher.

Pim French, L. Erdem Eraslan, J. M. Kros, H. M. Oosterkamp, A. M. E. Walenkamp, L. Beerepoot, M. Hanse, J. Buter, A. Honkoop, B. van der Holt, R. M. Vernhout, P. A. E. Sillevis Smitt, W. Taal

ORCID

, M. J. van den Bent

Identification of patients with recurrent gbm that benefit from bevacizumab.

Download from academic.oup.com

This paper is made freely available by the publisher.

J. Kraan

ORCID

, P. van den Broek, C. Verhoef, Dj J. Grunhagen, W. Taal

ORCID

, Jw W. Gratama, S. Sleijfer

Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells

Download from www.nature.com

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

L. A. Gravendeel, M. J. van den Bent, W. Taal

ORCID

, C. C. D. van der Rijt, J. E. C. Bromberg

P07.03recurrent Medulloblastoma and CNS Pnet in Adults - Results of Vip Chemotherapy

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Walter Taal

ORCID

, Roelien Enting, Martin Taphoorn, Marion Smits, Hendrikus Dubbink, Laurens Beerepoot, Monique Hanse, Linda Bralten, Hendrika Oosterkamp, Annemiek Walenkamp, Jan Buter, Aafke Honkoop, Dolf Boerman, Filip de Vos, Jacoline Bromberg and 3 other authors

At-55final Analysis of the Belob Trial (A Randomized Phase Ii Study on Bevacizumab Versus Bevacizumab Plus Lomustine Versus Lomustine Single Agent in Recurrent Glioblastoma) and First Radiology Review Results

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

W. Taal

ORCID

, H. M. Oosterkamp, A. M. E. Walenkamp, H. J. Dubbink, L. Beerepoot, M. Hanse, J. Buter, A. Honkoop, D. Boerman, F. Y. F. Vos, W. N. M. Dinjens, R. H. Enting, M. J. B. Taphoorn, F. W. P. J. van den Berkmortel, R. Jansen and 6 other authors

O10.05final Analysis of the Belob Trial (A Randomized Phase Ii Study on Bevacizumab Versus Bevacizumab Plus Lomustine Versus Lomustine Single Agent in Recurrent Glioblastoma) and First Radiology Review Results

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Lale Erdem Eraslan, Martin van den Bent, Johan Kros, Hendrika Oosterkamp, Annemiek Walenkamp, Laurens Beerepoot, Monique Hanse, J. Buter, Aafke Honkoop, Bronno van der Holt, R. M. Vernhout, Peter Sillevis Smitt, Walter Taal

ORCID

, Pim French

Ge-10identification of Patients With Recurrent GBM That Benefit From Bevacizumab

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Walter Taal

ORCID

, Karin van der Rijt, Winand Dinjens, Peter Sillevis Smitt, Agnes Wertenbroek, Jacoline Bromberg, Irene van Heuvel, Johan Kros, Martin van den Bent

At-56treatment of Large Low-Grade Oligodendroglial Tumors With Upfront Procarbazine, Lomustine, and Vincristine Chemotherapy With Long Follow-Up: A Retrospective Cohort Study With Growth Kinetics

Upload

This paper is made freely available by the publisher.

2012 Jeong Hoon Kim, Arnab Charkravarti, Meihua Wang, Kenneth Aldape, Erik Sulman, Markus Bredel, Monika Hegi, Mark Gilbert, Walter Curran, Maria Werner-Wasik, Minesh Mehta, Martin J. van den Bent, Alba A. Brandes, Martin J. Taphoorn, Johan M. Kros and 123 other authors

Clin-Medical + Radiation Therapies

Download from academic.oup.com

This paper is available in a repository.

Walter Taal

ORCID

, Joyce M. W. Segers-Van Rijn, Johan M. Kros, Irene van Heuvel, Carin C. D. van der Rijt

ORCID

, Jacoline E. Bromberg, Peter A. E. Sillevis Smitt, Martin J. van den Bent

Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study

Download from www.ncbi.nlm.nih.gov

Missing publications? Search for publications with a matching author name.